Oncology Impact Fund 2, L.P.
MPM BioImpact · adviser of record: MPM Asset Management LLC · 2019 vintage
Oncology Impact Fund 2, L.P. is a 2019 venture fund managed by MPM BioImpact, with $327mm raised (Form D, amount sold). It reported $1bn in gross assets at year-end 2025, 3.07x its size, its highest reported value.
- Latest value held
- $1bn year-end 2025
- Peak
- $1bn year-end 2025
- Fund size
- $327mm Form D, amount sold
- Held vs. size
- 3.07x peak 3.07x
Value held by year-end
Gross asset value reported on Form ADV at each year-end. Dashed line: fund size. Open in the Fund Tracker
| Year-end | Gross assets | ÷ size | Change |
|---|---|---|---|
| 2025 | $1bn | 3.07x | +21% over 2 yrs |
| 2023 | $826mm | 2.53x | -0% |
| 2022 | $828mm | 2.53x | -3% |
| 2021 | $856mm | 2.62x | +30% |
| 2020 | $657mm | 2.01x | +10% |
| 2019 | $598mm | 1.83x | – |
Other funds from MPM BioImpact
- MPM Bioventures 2022, L.P. 2022
- MPM Bioventures 2018, L.P. 2017
- MPM Bioventures 2018 (B), L.P. 2017
- MPM Asset Management Investors BV2014 LLC 2017
- MPM Asset Management Investors BV2018 LLC 2017
- MPM Asset Management Investors BV5 LLC 2017
- MPM Asset Management Investors BV4 LLC 2017
- MPM Asset Management Investors Sunstates Fund LLC 2017
- MPM Asset Management Investors 2003 Bviii LLC 2017
- MPM Oncology Innovations Fund L.P. 2016
- Ubs Oncology Impact Fund L.P. 2014
- MPM Bioventures 2014, L.P. 2014
About these numbers
Gross asset value is what the manager reports holding in the fund at each fiscal year-end, on SEC Form ADV, Schedule D. It includes the GP’s own commitment and is before carried interest, so it is not the LPs’ net return, and it does not show cash already distributed. A fall in value can mean distributions, markdowns or both. Fund size is the amount sold reported on Form D, which for some funds reflects only a first close. Private fund ID 805-6509560883. Data updated October 13, 2026.
Is this your fund?
Spot an error and email a correction. Facing DPI pressure? See how distribution financing works.